Markets:

Overview

News

Currencies

International

Treasuries

Kymera Therapeutics, Inc. - Common Stock (NQ:KYMR)

114.21 +2.13 (+1.90%)

Streaming Delayed Price Updated: 10:34 AM EDT, Jul 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Kymera Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Kymera Announces Positive Results from Phase 1 Clinical Trial Evaluating KT-474 in Patients with HS and AD and Sanofi’s Decision to Advance KT-474 into Phase 2 Clinical Trials

December 14, 2022

From Kymera Therapeutics, Inc.

Via GlobeNewswire

JetBlue Airways, Pacira BioSciences And Some Other Big Stocks Moving Lower On Tuesday ↗

December 13, 2022

U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 70 points on Tuesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Preclinical Data from Kymera Therapeutics’ Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLBCL at the American Society of Hematology Annual Meeting

December 12, 2022

From Kymera Therapeutics, Inc.

Via GlobeNewswire

What 4 Analyst Ratings Have To Say About Kymera Therapeutics ↗

December 06, 2022

Via Benzinga

Looking Into Kymera Therapeutics's Return On Capital Employed ↗

November 22, 2022

Via Benzinga

Where Kymera Therapeutics Stands With Analysts ↗

November 08, 2022

Analysts have provided the following ratings for Kymera Therapeutics (NASDAQ:KYMR) within the last quarter:

Via Benzinga

5 Analysts Have This to Say About Kymera Therapeutics ↗

November 08, 2022

Analysts have provided the following ratings for Kymera Therapeutics (NASDAQ:KYMR) within the last quarter:

Via Benzinga

Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting

December 11, 2022

From Kymera Therapeutics, Inc.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022 ↗

December 06, 2022

Via Benzinga

5 Analysts Have This to Say About Kymera Therapeutics ↗

November 04, 2022

Kymera Therapeutics (NASDAQ:KYMR) has observed the following analyst ratings within the last quarter:

Via Benzinga

Recap: Kymera Therapeutics Q3 Earnings ↗

November 03, 2022

Kymera Therapeutics (NASDAQ:KYMR) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

JPMorgan To Rally Around 17%? Here Are 10 Other Price Target Changes For Tuesday ↗

December 06, 2022

Via Benzinga

Kymera Therapeutics Provides Webcast Information for December 14 Investor Event

December 01, 2022

Company to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline

From Kymera Therapeutics, Inc.

Via GlobeNewswire

Kymera Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Business Update

November 03, 2022

From Kymera Therapeutics, Inc.

Via GlobeNewswire

5 Analysts Have This to Say About Kymera Therapeutics ↗

August 10, 2022

Within the last quarter, Kymera Therapeutics (NASDAQ:KYMR) has observed the following analyst ratings:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2022 ↗

November 08, 2022

Upgrades

Via Benzinga

Kymera Therapeutics Appoints Biopharmaceutical Leader Victor Sandor, M.D.C.M., to Board of Directors

November 03, 2022

From Kymera Therapeutics, Inc.

Via GlobeNewswire

Kymera Therapeutics to Report Third Quarter 2022 Results on November 3

October 20, 2022

Company also presenting at upcoming investor conferences

From Kymera Therapeutics, Inc.

Via GlobeNewswire

Kymera Therapeutics to Hold Investor Webcast on December 14 to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline

October 13, 2022

From Kymera Therapeutics, Inc.

Via GlobeNewswire

Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary ↗

September 15, 2022

Via Benzinga

Kymera Gets Orphan Drug Status For Rare Blood Cancer Candidate ↗

September 15, 2022

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Kymera Therapeutics’ (NASDAQ: KYMR) product candidate KT-333 for the treatment of Cutaneous T-cell Lymphoma (CTCL).

Via Benzinga

Looking Into Kymera Therapeutics's Return On Capital Employed ↗

September 02, 2022

Kymera Therapeutics (NASDAQ:KYMR) brought in sales totaling $11.51 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 9.74%, resulting in a loss of $40.26...

Via Benzinga

Where Kymera Therapeutics Stands With Analysts ↗

August 29, 2022

Over the past 3 months, 6 analysts have published their opinion on Kymera Therapeutics (NASDAQ:KYMR) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Insiders Buying Ecolab, Kymera Therapeutics And This Consumer Cyclical Stock ↗

August 24, 2022

Although US stocks closed mostly lower on Tuesday, there were a few notable insider trades.

Via Benzinga

Kymera Therapeutics Stock Scores Rising Relative Price Strength ↗

August 22, 2022

Kymera Therapeutics stock hit a key performance benchmark, with its Relative Strength Rating upgradedjulie mak to 94.

Via Investor's Business Daily

Kymera Therapeutics: Q2 Earnings Insights ↗

August 09, 2022

Kymera Therapeutics (NASDAQ:KYMR) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022 ↗

August 03, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 15, 2022 ↗

August 15, 2022

Via Benzinga

Kymera Therapeutics Commences Initial-Stage Oncology Trials ↗

June 15, 2022

Kymera Therapeutics, Inc. (NASDAQ: KYMR) has recently initiated dosing of patients in separate Phase 1 clinical trials evaluating its oncology drug candidates KT-333 and KT-413.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022 ↗

July 20, 2022

Upgrades

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.